Two Financial Analysis Firms Initiate Coverage of AB Science: A Closer Look

AB Science SA has caught the attention of two financial analysis firms, DNA Finance and In Extenso Finance, who have recently initiated coverage of the company. DNA Finance sees AB Science as a promising investment opportunity in the biotech sector, while In Extenso has gone a step further by issuing a strong buy opinion on the share.


AB Science SA has caught the attention of two financial analysis firms, DNA Finance and In Extenso Finance, who have recently initiated coverage of the company. DNA Finance sees AB Science as a promising investment opportunity in the biotech sector, while In Extenso has gone a step further by issuing a strong buy opinion on the share.

Strengthening Visibility and Investor Base


The decision by DNA Finance and In Extenso to cover AB Science is aimed at enhancing the company's visibility among both French and international institutional investors. This move is expected to broaden AB Science's investor base and attract more interest from the financial community. These new coverages complement the existing analysis provided by Chardan, a US-based investment bank specializing in biotechnologies and health technologies.

Both DNA Finance and In Extenso reports are now accessible on AB Science's website under the "Analysts coverage" section, providing investors with valuable insights into the company's potential and performance.

The Reader's Guide

Who Are DNA Finance and In Extenso?


DNA Finance is known for its expertise in equity research for listed companies in the healthcare sector, making them well-equipped to assess the opportunities presented by AB Science. On the other hand, In Extenso is a prominent provider of strategic consulting, valuation, and equity research services. With its listing sponsor status, In Extenso supports companies listed on various Euronext markets, including Euronext Growth and Euronext Access.

About AB Science


Founded in 2001, AB Science is a pharmaceutical company that focuses on the research, development, and commercialization of protein kinase inhibitors (PKIs). These inhibitors target specific proteins crucial in signaling pathways within cells, offering potential solutions for diseases with high unmet medical needs. The company's lead compound, masitinib, has already been approved for veterinary use and is undergoing development for human medicine in oncology, neurological diseases, inflammatory diseases, and viral diseases. Headquartered in Paris, France, AB Science is listed on Euronext Paris under the ticker symbol AB.

Forward-looking Statements and Risks


While AB Science is optimistic about its future prospects, it acknowledges the presence of risks and uncertainties that could impact its operations and financial performance. The company's forward-looking statements are based on projections, estimates, and assumptions that may not materialize as expected due to various unpredictable factors. These uncertainties include challenges related to product development, regulatory approvals, and market conditions that could affect the success of AB Science's endeavors.

In conclusion, the initiation of coverage by DNA Finance and In Extenso represents a significant milestone for AB Science, signaling growing interest and recognition within the financial community. Investors and stakeholders can now access comprehensive analysis and insights from these reputable firms, offering valuable information for decision-making.

For more information, please contact AB Science's Financial Communication & Media Relations team at [email protected].

Fateh Muhammad

Hey, I'm Fateh Muhammad, a Lahore local with a passion for arts and politics. My journey led me through the halls of the National College of Arts, where I delved into the intricacies of both disciplines. Now calling Lahore home, I'm here to share my insights and perspectives on the dynamic intersection of art and politics. Let's embark on this enlightening journey together! Connect With Me .